PTC Therapeutics Inc. (NASDAQ:PTCT) finished Friday with an addition of $1.04 to close at $41.68, an upside of 2.56 percent. An average of 561,980 shares of common stock have been traded in the last five days. There was a gain of $2.97 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 707,160 shares traded, while the 50-day average volume stands at 717,732.
PTCT stock has increased by 4.67% in the last month. The company shares reached their 1-month lowest point of $37.57 on 08/08/23. With the stock rallying to its 52-week high on 05/22/23, shares of the company touched a low of $33.25 and a high of $59.84 in 52 weeks. It has reached a new high 22 times so far this year and achieved 9.20% or $3.51 in price. In spite of this, the price is down -30.35% from the 52-week high.
Insider Transactions
PTCT stock investors should be aware that PTC Therapeutics Inc. (PTCT) stock had its last reported insider trading activity 66 days ago on Jun 07. In this transaction, the insider spent $44,860. Director, Reeve Emma, disposed of 2,652 shares at a price of $59.53 on May 23. The insider now owns more than $157,885 worth of shares. Prior to that, Director Reeve Emma went on to Sale 7,116 shares at $59.53 each on May 22. An amount of $423,630 was transacted.
Valuation Metrics
PTC Therapeutics Inc. (PTCT) stock’s beta is 0.37. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.18.
Financial Health
The quick ratio of PTC Therapeutics Inc. for the three months ended June 29 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. PTC Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -43.10%, while its operating margin for the same period stands at -77.30%. Its gross profit as reported stood at $654.12 million compared to revenue of $698.8 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, PTC Therapeutics Inc.’s return on assets was -39.70%.
Earnings Surprise
For the three-month period that ended June 29, PTC Therapeutics Inc. had $129.55 million in cash and short-term investments compared to $572.64 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$198.88 million in the quarter, while revenues of -$138.96 million were grew 23.53%. The analyst consensus anticipated PTC Therapeutics Inc.’s latest quarter earnings to come in at -$1.71 per share, but it turned out to be -$2.66, a -55.60% surprise. For the quarter, EBITDA amounted to $59.82 million. Shareholders own equity worth $75.34 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at PTC Therapeutics Inc. (PTCT) price momentum. RSI 9-day as of the close on 11 August was 62.59%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.72%.
As of today, PTCT’s price is $39.83 +7.67% or $2.97 from its 5-day moving average. PTCT is currently trading +6.38% higher than its 20-day SMA and -14.04% lower than its 100-day SMA. However, the stock’s current price level is -0.69% below the SMA50 and -8.68% below the SMA200.
The stochastic %K and %D were 74.45% and 54.66%, respectively, and the average true range (ATR) was 1.51. With the 14-day stochastic at 89.93% and the average true range at 1.52, the RSI (14) stands at 56.15%. The stock has reached 0.83 on the 9-day MACD Oscillator while the 14-day reading was at 0.88.
Analyst Ratings
SVB Securities launched coverage on PTC Therapeutics Inc. (NASDAQ: PTCT) in its analyst report released on March 17, 2023. The firm assigned the stock a Market perform rating. The consensus rating for PTC Therapeutics Inc. (PTCT) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell PTCT, while 7 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.
What is PTCT’s price target for the next 12 months?
Analysts predict a range of price targets between $35.00 and $73.00, with a median target of $49.00. Taking a look at these predictions, the average price target given by analysts for PTC Therapeutics Inc. (PTCT) stock is $51.87.
